<DOC>
	<DOC>NCT01371344</DOC>
	<brief_summary>The purpose of this study, a follow up to study FG506-CL-0403, is to see how safe and effective Modigraf® is (Part A) and to see how safe and effective it is to change your child's medication from Modigraf® to Prograf® (Part B).</brief_summary>
	<brief_title>A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients</brief_title>
	<detailed_description>To monitor the safety and efficacy of Modigraf® (tacrolimus granules) in stable paediatric allograft recipients (Part A) and to monitor dose changes and tacrolimus whole blood trough levels after conversion from a Modigraf based Immunosuppression regimen to a Prograf® based Immunosuppression regimen (Part B).</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>F506CL0404 Part A Subject was ≤12 years of age at enrolment into study F506CL0403 Subject received at least one dose of Modigraf in the F506CL0403 study F506CL0404 Part B Subject received at least one dose of Modigraf in the F506CL0403 study Subject participated in F506CL0404 Part A Subject has continuously been dosed with Twice daily (BID) Modigraf since the End of Study Visit for Part A (ESVA) from F506CL0404 Part A Subject is stable and has had no dose changes in the preceding 2 weeks F506CL0404 Part A As all subjects included in this study conform to the exclusion criteria in study F506CL0403, hence no specific exclusion criteria are relevant for this study F506CL0404 Part B There are no specific exclusion criteria for this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>